Physician profile
David Neubauer
NPI 1427001296
$58,578.90
in general payments reported to CMS, 2019-2025
7 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,830 · 2020: $16K · 2021: $1,800 · 2022: $692 · 2023: $3,646 · 2024: $19K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $10K · Food and Beverage: $730 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,632.50 |
| Travel and Lodging | $10,369.32 |
| Food and Beverage | $730.46 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23,666.60 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $22,951.88 | 2023-2025 | Quviviq, Quviviq |
| Janssen Global Services, LLC | $10,420.69 | 2024-2025 | |
| Eisai Co., LTD. | $1,200.00 | 2024 | |
| Harmony Biosciences LLC | $223.77 | 2023-2025 | Wakix |
| Neurocrine Biosciences, INC. | $80.03 | 2019 | |
| Axsome Therapeutics, INC. | $35.93 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neubauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.